Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial
남아프리카 공화국의 유아 및 유아에 대한 비경구 P2-VP8-P[8] 서브유닛 로타바이러스 백신의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조 시험
Articles
[키워드] 95% CI
adjusted
adverse event
adverse events
African
approach
assigned
benefit
block
Block randomisation
Cohort
computer-generated
different dose
different doses
dose
dose-escalation
doses
double-blind
eligible
Endpoint
enrolled
finding
FIVE
followed by
foundation
Frequency
funding
geometric mean
geometric mean titre
geometric mean titres
groups
healthy
highest
HIV-uninfected
homologous
hospital
IgA
IgG
IgG seroresponse
immunogenic
immunogenicity
Infant
Infants
injection
Injections
Laboratory
live oral rotavirus vaccines
Local
Melinda Gate
Melinda Gates
Mild
neutralising antibody
neutralising antibody seroresponse
neutralising antibody seroresponses
nine
non-replicating rotavirus vaccine
occurred
offer
oral rotavirus vaccine
oral vaccines
parent
Parenteral
parents
participant
Placebo
placebo group
placebo-controlled
placebo-controlled trial
primary immunogenicity
randomisation
randomised
reaction
receiving
reduced
Registered
Research
rotavirus
rotavirus disease
rotavirus vaccination
rotavirus vaccine
Safety
safety analysis
safety endpoint
Serious Adverse Event
Serious Adverse Events
Serum IgA seroresponse
Serum IgA seroresponses
Seven
severity
South
South Africa
subunit
Subunit vaccine
systemic reaction
systemic reactions
the placebo group
those receiving placebo
Treatment
Trial
trivalent
vaccination
Vaccine
was done
was used
[DOI] 10.1016/S1473-3099(17)30242-6 PMC 바로가기 [Article Type] Articles
[DOI] 10.1016/S1473-3099(17)30242-6 PMC 바로가기 [Article Type] Articles